IL-6 Trans-Signaling Loop in CAR-T Cytokine Release Syndrome

CAR-T Engagement

CAR-T dose / antigen engagement 60%

IL-6 trans-signaling gain 70%

Tocilizumab (anti-IL-6R) dose 0%

Live Readouts

Serum IL-6

12 pg/mL

Core temp

37.0°C

Loop growth rate

0.00 /h

Tumor burden

100%

ASTCT-style CRS grade (fever-driven proxy)

Grade 0 — no CRS

How it works

When CAR-T cells engage tumor antigen they release IFN-γ and other signals that activate bystander macrophages/monocytes, which secrete IL-6. Most cells only express membrane IL-6R (classic, largely anti-inflammatory signaling), but IL-6 can also bind soluble IL-6R and dock onto gp130 on cells that lack membrane IL-6R — including endothelium. This trans-signaling route drives further IL-6, MCP-1 and VEGF production, a positive feedback loop that is the accepted mechanistic driver of severe CRS:

dIL6/dt = k_car·dose·Tumor  +  G_eff·IL6  −  k_clear·IL6
G_eff    = k_trans · (1 − tocilizumab_dose)
dTumor/dt = −k_kill·dose·Tumor
dTemp/dt  = k_temp·(IL6 − IL6_base) − k_relax·(Temp − 37°C)

CAR-T dose sets both the direct IL-6 drive and how fast tumor burden falls.
Trans-signaling gain is the loop's self-reinforcing rate constant, G_eff. When G_eff exceeds the clearance rate k_clear the loop is super-linear — IL-6 grows exponentially instead of settling: an in-silico cytokine storm.
Tocilizumab is a real, FDA-approved anti-IL-6R monoclonal antibody used to treat CRS. In the model it multiplies G_eff toward zero, which is exactly its mechanism — blocking IL-6 receptor engagement (both classic and trans-signaling) rather than removing IL-6 itself.

The vessel in the scene reddens and its wall widens (capillary leak proxy) as IL-6 rises; the orbiting particles are IL-6 molecules streaming from activated macrophages onto the endothelium. This is a simplified teaching model of a real, published mechanism (Nature Reviews Clinical Oncology, Shimabukuro-Vornhagen et al. 2018; Kang et al., trans-signaling in IL-6 biology) — not a calibrated clinical predictor.

Macrophages CAR-T cells Tumor cells IL-6 molecules

⚠ Couldn't load the 3D engineThree.js failed to load from the CDN. Check your connection and reload.